1. Home
  2. BAFN vs ITRM Comparison

BAFN vs ITRM Comparison

Compare BAFN & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BAFN
  • ITRM
  • Stock Information
  • Founded
  • BAFN 1999
  • ITRM 2015
  • Country
  • BAFN United States
  • ITRM Ireland
  • Employees
  • BAFN N/A
  • ITRM N/A
  • Industry
  • BAFN Savings Institutions
  • ITRM Biotechnology: Pharmaceutical Preparations
  • Sector
  • BAFN Finance
  • ITRM Health Care
  • Exchange
  • BAFN Nasdaq
  • ITRM Nasdaq
  • Market Cap
  • BAFN 40.6M
  • ITRM 40.0M
  • IPO Year
  • BAFN N/A
  • ITRM 2018
  • Fundamental
  • Price
  • BAFN $9.88
  • ITRM $0.73
  • Analyst Decision
  • BAFN
  • ITRM Strong Buy
  • Analyst Count
  • BAFN 0
  • ITRM 1
  • Target Price
  • BAFN N/A
  • ITRM $9.00
  • AVG Volume (30 Days)
  • BAFN 15.0K
  • ITRM 918.1K
  • Earning Date
  • BAFN 10-30-2025
  • ITRM 11-13-2025
  • Dividend Yield
  • BAFN 3.36%
  • ITRM N/A
  • EPS Growth
  • BAFN 100.65
  • ITRM N/A
  • EPS
  • BAFN 1.89
  • ITRM N/A
  • Revenue
  • BAFN $78,211,000.00
  • ITRM N/A
  • Revenue This Year
  • BAFN N/A
  • ITRM N/A
  • Revenue Next Year
  • BAFN N/A
  • ITRM $482.25
  • P/E Ratio
  • BAFN $5.04
  • ITRM N/A
  • Revenue Growth
  • BAFN 0.67
  • ITRM N/A
  • 52 Week Low
  • BAFN $6.40
  • ITRM $0.61
  • 52 Week High
  • BAFN $19.75
  • ITRM $3.02
  • Technical
  • Relative Strength Index (RSI)
  • BAFN 54.13
  • ITRM 49.37
  • Support Level
  • BAFN $9.32
  • ITRM $0.67
  • Resistance Level
  • BAFN $10.38
  • ITRM $0.76
  • Average True Range (ATR)
  • BAFN 0.37
  • ITRM 0.05
  • MACD
  • BAFN -0.02
  • ITRM -0.00
  • Stochastic Oscillator
  • BAFN 39.16
  • ITRM 33.18

About BAFN BayFirst Financial Corp.

BayFirst Financial Corp is a bank holding company, it generates its revenue from interest on loans and the gain-on-sale income derived from the sale of loans into the secondary market. The company serves a broad spectrum of individuals, families, and small businesses, supported by national business lines in residential and SBA lending and technology platforms. The primary source of funding for its loans is deposits. BayFirst measures performance through net interest income after provision for loan losses, return on average assets, and return on average common equity, while maintaining appropriate regulatory leverage and risk-based capital ratios. The company has various segment such as Real Estate(Residential, Commercial, and Construction & Land), Commercial and Industrial, Consumer.

About ITRM Iterum Therapeutics plc

Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.

Share on Social Networks: